DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Levofloxacin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
Currently, fluoroquinolones are second only to cephalosporins and penicillins on the antibacterial market. Levofloxacin, a third-generation fluoroquinolone, was developed by Daiichi Pharmaceutical Co., Ltd. (merged with Sankyo Co., Ltd. into "Daiichi Sankyo" in 2005) and first marketed in Japan in 1994.
In 1995, Levofloxacin APIs and tablets manufactured by Daiichi Pharmaceutical Co., Ltd. were admitted to the Chinese market. After that, Daiichi Pharmaceutical Co., Ltd. established its Chinese subsidiary Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. with an investment of USD 50 million. The subsidiary produces Levofloxacin preparations in China with the APIs from its parent company.
The Levofloxacin tablets produced in China were launched in 1996 under the trade name Cravit. At that time, the retail price was about 7 CNY/tablet. Effective and inexpensive, Cravit saw its sales value rising on the Chinese market. Later, some Chinese companies developed generic Levofloxacin, and extended the dosage forms from tablets to injections, capsules, gels, etc.
According to market research, in 1998 when it had been launched in China for over one year, Levofloxacin became one of the top 100 drugs by sales value, and then showed an upward trend. The sales value of Levofloxacin declined from 2016 to 2017 after it reached CNY 1.23 billion in 2015.
In 2017, China's Levofloxacin market was dominated by Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd., Yangtze River Pharmaceutical (Group) Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., and Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory.
By sales value, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. captured a market share of 29.1%. The injections, tablets, and eye drops accounted for about 63%, 20% and 13.7% respectively of China's Levofloxacin market. The other dosage forms had a small market share.
As environmental pollution and population aging intensify in China, there will be higher incidences of the main indications for Levofloxacin, for example, respiratory infection, urinary infection and intestinal infection. It is expected that China's Levofloxacin market will still have some growth potential from 2018 to 2022.
- China Resources Double-Crane Pharmaceutical Co. Ltd.
- Daiichi Sankyo Pharmaceutical (Beijing) Co. Ltd. (Cravit)
- Santen Pharmaceutical Co. Ltd.
- Xinchang Pharmaceutical Factory
- Yangtze River Pharmaceutical (Group) Co. Ltd. (Zuoke)
- Zhejiang Medicine Co. Ltd.
- Xinchang Pharmaceutical Factory (Lailixin)
- Development environment of Levofloxacin in China
- Market size of Levofloxacin in China
- Competitive landscape of China's Levofloxacin market
- Prices of Levofloxacin in China
- Prospect of China's Levofloxacin market from 2018 to 2022
List of Chapters
1 Relevant Concepts of Levofloxacin
2 Sales of Levofloxacin in China, 2013-2017
3 Analysis on Major Levofloxacin Manufacturers in China, 2013-2017
4 Prices of Levofloxacin in China, 2017-2018
5 Prospects of China's Levofloxacin Market, 2018-2022
For more information about this report visit https://www.researchandmarkets.com/research/hmjxl3/investigation?w=4